Literature DB >> 16210067

Adverse reactions to biologic agents: focus on autoimmune disease therapies.

Susan J Lee1, Arthur Kavanaugh.   

Abstract

In recent years, a growing number of biologic agents have become available for the treatment of various autoimmune, neoplastic, cardiovascular, infectious, allergic, and other conditions. Their introduction has resulted in marked clinical improvements for many patients. Nevertheless, a variety of adverse reactions have been observed with these agents. Because many biologic agents affect key components of sundry physiologic processes, a number of important adverse reactions might be considered mechanism based. Other adverse reactions relate to the agent rather than the target, including hypersensitivity reactions. As a means of exploring the spectrum of potential adverse effects related to biologic agents and their mechanisms, this review will focus on the experience to date with biologic agents used for the treatment of autoimmune disorders. An understanding of the spectrum and types of reactions possible with biologic agents, as well as the mechanisms underlying such reactions, will help clinicians use them optimally.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16210067     DOI: 10.1016/j.jaci.2005.03.028

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  14 in total

Review 1.  Biological therapy and dentistry: a review paper.

Authors:  Lida Radfar; Roshanak E Ahmadabadi; Farah Masood; R Hal Scofield
Journal:  Oral Surg Oral Med Oral Pathol Oral Radiol       Date:  2015-07-31

2.  Anti-tumour necrosis factor alpha therapy in patients with impaired renal function.

Authors:  Axel J Hueber; Andac Tunc; Georg Schett; Bernhard Manger
Journal:  Ann Rheum Dis       Date:  2007-03-02       Impact factor: 19.103

Review 3.  Control of autoimmune inflammation by celastrol, a natural triterpenoid.

Authors:  Shivaprasad H Venkatesha; Steven Dudics; Brian Astry; Kamal D Moudgil
Journal:  Pathog Dis       Date:  2016-07-11       Impact factor: 3.166

Review 4.  Kinase inhibitors and monoclonal antibodies in oncology: clinical implications.

Authors:  Helen Gharwan; Hunter Groninger
Journal:  Nat Rev Clin Oncol       Date:  2015-12-31       Impact factor: 66.675

5.  Adverse drug reactions of Rituximab in patients suffering from autoimmune neurological diseases.

Authors:  Niayesh Mohebbi; Maryam Taghizadeh-Ghehi; Seyed Mehrdad Savar; Siamak Abdi; Romina Kouhsari; Kheirollah Gholami; Shahriar Nafissi
Journal:  Daru       Date:  2022-09-24       Impact factor: 4.088

Review 6.  Treatment dilemmas of cetuximab combined with chemotherapy for metastatic colorectal cancer.

Authors:  Feng Wen; Qiu Li
Journal:  World J Gastroenterol       Date:  2016-06-21       Impact factor: 5.742

Review 7.  Evaluation and management of pediatric drug allergic reactions.

Authors:  Brett L Buchmiller; David A Khan
Journal:  Curr Allergy Asthma Rep       Date:  2007-11       Impact factor: 4.919

8.  Anti-TNF therapies: a comprehensive analysis of adverse effects associated with immunosuppression.

Authors:  Victoria Connor
Journal:  Rheumatol Int       Date:  2009-12-16       Impact factor: 3.580

9.  How the immune system responds to therapeutic biological agents.

Authors:  Alessandra Vultaggio; Giulia Petroni; Sara Pratesi; Francesca Nencini; Daniele Cammelli; Andrea Ferraro; Enrico Maggi; Andrea Matucci
Journal:  J Int Med Res       Date:  2016-09       Impact factor: 1.671

10.  Incidence of Pneumocystis jirovecii and Adverse Events Associated With Pneumocystis Prophylaxis in Children Receiving Glucocorticoids.

Authors:  Matthew L Basiaga; Michelle E Ross; Jeffrey S Gerber; Alexis Ogdie
Journal:  J Pediatric Infect Dis Soc       Date:  2018-12-03       Impact factor: 3.164

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.